文献速递造血干细胞移植与细胞治疗

基于移植后环磷酰胺预防GVHD的单倍体移植中社区呼吸道病毒感染的发生率与影响

Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation.
PubMed 文献 · Br J Haematol · 2021-06-14

该研究分析2012-2017年首次接受HCT的AML、ALL和MDS患者,比较SibCNI(N=1605)、SibCy(N=403)和HaploCy(N=757)三组的CRVIs发生率及移植结局。结果显示接受PTCy的患者CRVIs发生率更高,且HaploCy组在+180天前发生CRVI者治疗相关死亡风险和2年总生存均更差。

要点

  • 接受PTCy预防GVHD的患者CRVIs发生率高于CNI方案,与供者类型无关

核心结论

  • 接受PTCy的患者CRVIs发生率更高,且HaploCy组发生CRVI与治疗相关死亡增加和总生存劣化相关。

研究设计与样本

  • 回顾性分析2012-2017年首次接受HCT的急性髓系白血病、急性淋巴细胞白血病和骨髓增生异常综合征患者。
  • 比较SibCNI(N=1605)、SibCy(N=403)和HaploCy(N=757)三组的CRVIs发生率及移植结局。

主要发现

  • 接受PTCy的患者CRVIs发生率更高,无论供者类型。

临床怎么用

  • 对接受PTCy预防GVHD的单倍体移植患者应加强CRVIs监测与防治,以改善长期生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Community respiratory viral infections (CRVIs) are associated with pulmonary function impairment, alloimmune lung syndromes and inferior survival in human leucocyte antigen (HLA)-matched allogeneic haematopoietic stem cell transplant (HCT) recipients. Although the incidence of viral infections in HLA-haploidentical HCT recipients who receive post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis is reportedly increased, there are insufficient data describing the incidence of CRVIs and the impact of donor source and PTCy on transplant outcomes. Analysing patients receiving their first HCT between 2012 and 2017 for acute myeloid leukaemia, acute lymphoblastic leukaemia and myelodysplastic syndromes, we describe comparative outcomes between matched sibling transplants receiving either calcineurin-based GVHD prophylaxis (SibCNI, N = 1605) or PTCy (SibCy, N = 403), and related haploidentical transplants receiving PTCy (HaploCy, N = 757). The incidence of CRVIs was higher for patients receiving PTCy, regardless of donor type. Patients in the HaploCy cohort who developed a CRVI by day +180 had both a higher risk of treatment-related mortality [hazard ratio (HR) 2⋅14, 99% confidence interval (CI) 1⋅13-4⋅07; P = 0⋅002] and inferior 2-year overall survival (HR 1⋅65, 99% CI 1⋅11-2⋅43; P = 0⋅001) compared to SibCNI with no CRVI. This finding justifies further research into long-term antiviral immune recovery, as well as development of preventive and treatment strategies to improve long-term outcomes in such patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Mulroney CM, Abid MB, Bashey A, et al. Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation. Br J Haematol. 2021. PMID: 34124796. doi:10.1111/bjh.17563

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。